Company Overview and News

Private Sydney: Nothing negative about this African teenager's story

Those African teenagers have been getting a bad rap in the mainstream media in recent times, but if you look a little harder there are a few positive stories coming out of Australia's refugee community that are not generating quite as much press: namely the global conquest by 18-year-old model Adut Akech.
Upvote Downvote

Private Sydney: Erica Packer quietly returns to Sydney with kids

As James Packer continues to battle his demons in Boston at America’s most exclusive mental health facility, once home to A Beautiful Mind mathematician John Nash, so too have his former wife and three children been treated to some much needed respite.
Upvote Downvote

Why it’s finally time to ban mortgage broker commissions

Something is rotten in Australia’s $1.6 trillion mortgage market. That is the inescapable conclusion of the explosive first week of hearings of the Turnbull government’s bank royal commission, which continue today.
Upvote Downvote

Non-bank lenders attracting investors

Non-bank lenders, Chifley Securities has benefited from the low interest rate environment with a record level of loans worth $1.87 billion for the 2017 calendar year.
Upvote Downvote

Dodgy loans under spotlight for opening round of banking royal commission

Fraudulent brokers and loan applications at National Australia Bank and the Commonwealth Bank-owned Aussie Home Loans are top of the agenda for examination when the royal commission kicks off in a fortnight.
Upvote Downvote

Competition heats up among lenders for first home buyers, investors

Banks are likely to compete more fiercely to lend money to first home buyers and property investors as they seek out growth in a home loan market that is going "sideways," Mortgage Choice says.
Upvote Downvote

Macquarie Group's (MCQEF) on Operational Briefing Broker Conference (Transcript)

2018-02-06 seekingalpha
Good morning, everyone. Welcome to Macquarie's 2018 Operational Briefing. For those who don’t know me, I’m Sam Dobson, the Head of Investor Relations.
Upvote Downvote

Property sellers target brokers and planners with payments for client referrals

Real estate sales companies are using big commissions to tempt mortgage brokers, financial planners and accountants to sell overpriced properties to unsuspecting clients.
Upvote Downvote

Are you ready for a rate rise?

The good news is small businesses are currently being charged the lowest interest rates they have paid since the Reserve Bank of Australia started collecting this data back in 1993.
Upvote Downvote

Ignore mortgages’ mental barriers

MOVING a mortgage to a new lender appears to produce plenty of hurdles, although many of them are imagined.
Upvote Downvote

Show a broker you know loans

MORTGAGE brokers are helpful for house hunters navigating the huge range of loan products on the market.
Upvote Downvote

Haggling key to better home loan rates

BANKS will budge on their home loan rates if savvy customers demand an on-the-spot deal, new findings have revealed.
Upvote Downvote

Big savings as banks slash rates

INTEREST rate uncertainty continues to spook Australian borrowers, who are rushing to lock in their home loans, encouraged by recent fixed rate cuts by major banks.
Upvote Downvote

Citi names 87 suburbs across Australia where apartment owners will be face stricter mortgage hurdles

Apartment buyers in almost 90 suburbs across Australia – including swathes of Sydney, Melbourne and Brisbane – will face tougher hurdles to get a mortgage as one lender cracks down on its loan criteria. And experts say more could do the same.
Upvote Downvote

Home ownership not a priority for one in three: Rising prices 'changing Australian culture'

The Great Australian Dream of owning your own home – usually a house on a quarter-acre block – is almost considered a universal truth. But one in every three people no longer holds onto this aspiration, a new survey reveals.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...